Connectivity and computing power change life
Leading stock of biopharmaceuticals:
1. Fengyuan Pharmaceutical (000153)
the company has signed the "joint venture contract" with Anhui Zhongren Technology Co., Ltd. to establish Anhui Fengyuan Zhongren Pharmaceutical Co., Ltd., which is engaged in R & D, proction and sales of new implant drugs
2. Anke bio (300009)
cooperated with Hefei medical engineering pharmaceutical on the proction technology, new drug certificate and proction approval transfer of tegafur tablets. Tegafur tablet was developed by Hefei medical engineering and Pharmaceutical Co., Ltd., and obtained clinical approval in 2007. At present, clinical trials are in progress, and it is expected to be put into proction and sale in 2012
3. The cancer gene targeted diagnostic reagents developed by PLO (000739)
Company have high barrier characteristics. Data show that the project is to use human genetic genomics technology to target cancer, use cloned protein or natural protein as probe, carry contrast agent, and inject it into human body in the form of injection
can be used to confirm the size of cancer cells and whether drug treatment is needed. In addition, Baishi, which is exclusively proced by Puluo, is a national class II new anticancer drug. At present, shixin has become the first choice for cancer treatment in hospitals at county level and above in Zhejiang Province, as well as major hospitals in Guangdong, Beijing, Jiangsu and other provinces, with annual sales of more than 80 million yuan
4. Hengrui Pharmaceutical (600276)
tegafur capsule is an oral anticancer agent derived from fluorouracil, which was officially approved at the end of August 2010 and began proction in September. This year and next, it will become the first-line variety of anti-tumor proct line, and it is estimated that the sales scale of this variety will reach 400-600 million yuan / year
holding subsidiary Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. and Jiangsu Provincial Department of science and technology signed the contract on the special fund project for the transformation of scientific and technological achievements in Jiangsu Province; R & D and instrialization of recombinant human endostatin injection & quot; The project was supported by the special fund for the transformation of scientific and technological achievements in Jiangsu Province
the data showed that recombinant human endostatin injection is a national class I biological anticancer drug with independent intellectual property rights, and was awarded the national & quot; in 2006; 863" Project support for non-small cell lung cancer. At present, the project is in the stage of applying for phase III clinical research. The acquisition of funds for this project will provide an important financial guarantee for phase III clinical research and future instrialization of the project
6. Haixin Co., Ltd. (600851)
Haixin biotechnology, a holding subsidiary of the company, was developed in cooperation with Shanghai Second Military Medical University; Antigen sensitized human dendritic cells APDC), which can be used for the treatment of rectal cancer, is the first self-developed APDC therapeutic vaccine for advanced colorectal cancer officially approved by the State Food and Drug Administration in China
at present, the market of colorectal cancer drugs is vast. The market capacity of anti colorectal cancer drugs in several major countries alone is more than US $1.7 billion, and it is estimated that the profit margin of anti-cancer drugs can reach more than 80%
The company's main procts include a class of new anticancer drugs, recombinant human interleukin-2 for injection, which is used for comprehensive treatment of renal cancer, malignant melanoma and other malignant tumors 8. Southwest synthetic (000788):
conprehibin disodium phosphate (CA4P) and its injection are a kind of vascular targeting drug or endothelial destruction drug
9. Fosun Pharmaceutical (600196):
the monoclonal antibody drug project built by the company and chemo group, an international pharmaceutical enterprise, on Shanghai kaimao biomedical platform will introce four monoclonal antibodies for tumor treatment and risk-related diseases
10. Haizheng Pharmaceutical (600267)
the company's preparation export base project under construction has an annual output of 25 million bottles of cytotoxic anti-tumor drug liquid injection, and the company's gene drug tumor necrosis factor receptor antibody fusion protein has entered the phase II clinical trial stage
11. ZHONGXIN PHARMACEUTICAL (600323):
the company's leading proct & quot; Anfuron & quot- Second generation genetic engineering α- 2B interferon
12. Hainan Haiyao (000566):
the company's main procts include anti-tumor drug paclitaxel injection, which can be used to treat ovarian cancer